Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • prognosFACTOR™
    • Marketplace
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey
      • Physician Segmentation
      • Outcomes
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
      • Risk Adjustment & Quality Analytics
  • Company
    • Careers
    • Events
    • News
    • Insights
  • Contact Us
Home Insights The Impact of COVID-19 on Lab Testing Trends at a National Level

The Impact of COVID-19 on Lab Testing Trends at a National Level

  • May 20, 2020
  • Posted in Lab Testing Trends

The pandemic has had a profound impact on healthcare, some long lasting and some fleeting, but important nevertheless. Prognos Health has been monitoring the impact COVID-19 has had on overall lab testing. While testing for all conditions has declined we’ve noted that lab testing volume at a national level is starting to rebound. 

Prognos uses a large representative sample from a subset of the company’s lab testing registry as a proxy for projections of national volume of testing and the trends are compared on a weekly basis year-to-date. The national trend in testing was relatively stable through mid-March. The first two weeks of the  shutdown showed a decrease in national lab testing trends of 23% and 38% weekly, for an overall drop of 53% over those two weeks. This lower volume persisted for some time, but we find it encouraging that the market trend has stabilized showing signs of recovery with three consecutive weeks of double-digit percentage increases. Data from the most recent period (week ending 5/8) shows an increase with a 21% increase over the prior week. 

This had a major impact on the healthcare ecosystem from patients needing to be routinely tested and monitored for medication levels to oncology testing vital to early diagnosis. For example, according to an article on MedScape, Clinicians, Researchers Adjust to COVID Cancer Upheaval, 60% of [prostate-specific antigen] tests are down as of the week before May 18th. 

This trend is both difficult and yet actionable. Understanding the trends in testing for your brand can better inform your alternative channels such as digital. In this article, 5 Ways to Immunize Your Pharma Brand Against the COVID-19 Downturn, the authors write about the opportunity to leverage digital marketing and e-detailing to better target HCPs during the age of COVID. Further, more granular brand-specific testing trends may be useful in direct field force redeployment strategies as the country begins responsible actions to reopen. 

Prognos offers its customers more granular testing trends including brand level or regional and local levels. For more information on Prognos lab testing trends contact us.
« The Virtue in Virtual: How COVID-19 is Forcing Increased Digital Outreach
Lab Testing Trends Year-to-Date Through May 8 »

Categories

  • AI
  • Alerts
  • Clinical
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Omnichannel Marketing
  • Physician Segmentation
  • Prog Spotlight

Archives

Latest Tweets

Prognos HealthFollow

Prognos Health
prognosAIPrognos Health@prognosAI·
22 Jan

Uncovering the (Clinical) Truth.

Bill Bowman and @olatulekan write about the intersection where #MachineLearning meets disease-specific #clinical knowledge - #ClinicalTruths - and how this improves #PatientOutcomes with #HealthcareAnalytics at scale.

https://prognoshealth.com/blog/uncovering-the-clinical-truth/

Reply on Twitter 1352709796135391237Retweet on Twitter 13527097961353912371Like on Twitter 13527097961353912371Twitter 1352709796135391237
prognosAIPrognos Health@prognosAI·
31 Dec

As we ring in the new year, there's so much to look forward to. We wish all of our clients, and partners a healthy, happy new year and are excited to continue innovating together in 2021 to positively impact care.

Reply on Twitter 1344647644669468672Retweet on Twitter 1344647644669468672Like on Twitter 13446476446694686722Twitter 1344647644669468672
prognosAIPrognos Health@prognosAI·
22 Dec

As this year comes to an end, our thoughts turn gratefully to our clients, partners, and the industry for an unwavering commitment to improving patient outcomes in the face of a global pandemic. We look forward with hope to innovating together in 2021 to positively impact care.

Reply on Twitter 1341473757291032582Retweet on Twitter 1341473757291032582Like on Twitter 13414737572910325821Twitter 1341473757291032582
Retweet on TwitterPrognos Health Retweeted
hikmapharmaHikma@hikmapharma·
21 Dec

In July we held a great discussion at our virtual #panel on digital health during the #COVID19 pandemic featuring panelists from @lemonaidhealth @prognosAI and @Click_Tx, some of @HikmaVentures' most exciting investments in digital health. #Top20of2020

Reply on Twitter 1340960230562287618Retweet on Twitter 13409602305622876182Like on Twitter 13409602305622876183Twitter 1340960230562287618
prognosAIPrognos Health@prognosAI·
16 Dec

2020 was filled with so many challenges, yet we’ve helped push the boundaries with our peers to accelerate change.

We ended the year on a high note and trust that 2021 will be brighter for us all!

https://prognoshealth.com/about-us/news/press-release/ends-innovative-year-with-award/

#Innovation #HealthTech #HealthAnalytics

Reply on Twitter 1339274462307475456Retweet on Twitter 1339274462307475456Like on Twitter 13392744623074754561Twitter 1339274462307475456
Load More...
  • prognosFACTOR™
    • Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • Events
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2021. All Rights Reserved.

See What Decision Speed Looks Like in Action

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.